Expert opinion on drug delivery最新文献_第9页

Recent advancements and future applications of intrauterine drug delivery systems. 宫内给药系统的最新进展和未来应用。

Expert opinion on drug delivery Pub Date : 2025-06-01 Epub Date: 2025-04-09 DOI: 10.1080/17425247.2025.2490266

Ashwin Abhang, Diane J Burgess

{"title":"Recent advancements and future applications of intrauterine drug delivery systems.","authors":"Ashwin Abhang, Diane J Burgess","doi":"10.1080/17425247.2025.2490266","DOIUrl":"10.1080/17425247.2025.2490266","url":null,"abstract":"Introduction: Intrauterine devices (IUDs) are drug-device combination products that are placed inside the uterus above the endometrium. IUDs contain a therapeutic agent used for contraception and have been shown to have other therapeutic benefits. Over the past century, intrauterine drug delivery systems (IUDDS) have revolutionized women's health, and they hold immense growth potential in the future for new developments in the therapeutic areas beyond contraception.Areas covered: The aim of this review is to offer a comprehensive description of the history, development, and current state of IUDDS, next-generation IUDDS, and future applications of IUDDS in therapeutic areas beyond contraception such as multi-purpose prevention technologies, hormone replacement therapy, endometriosis, uterine fibroids, and endometrial cancer.Expert opinion: The uterus's unique features make it an ideal site for controlled, prolonged, and localized delivery of drugs, ensuring maximum concentration at the target site. Currently, IUDs are the most widely used contraceptive method. Future IUDDS hold the potential to deliver therapeutic agents for broader therapeutic areas for women's health, potentially aiding in the treatment of various diseases and disorders of the female reproductive system. Further research in development, characterization, and translation is warranted to ensure IUDDS reach their potential in many areas of women's health.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"841-856"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143797501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The nasal route for nose-to-brain drug delivery: advanced nasal formulations for CNS disorders. 鼻至脑药物输送的鼻腔途径：用于中枢神经系统疾病的先进鼻腔配方。

Expert opinion on drug delivery Pub Date : 2025-06-01 Epub Date: 2025-04-07 DOI: 10.1080/17425247.2025.2489553

Paraskevi Papakyriakopoulou, Georgia Valsami

{"title":"The nasal route for nose-to-brain drug delivery: advanced nasal formulations for CNS disorders.","authors":"Paraskevi Papakyriakopoulou, Georgia Valsami","doi":"10.1080/17425247.2025.2489553","DOIUrl":"10.1080/17425247.2025.2489553","url":null,"abstract":"Introduction: The nasal route offers a feasible alternative to oral and/or parenteral administration, providing a noninvasive route to achieve nose-to-brain drug delivery involving the olfactory and trigeminal nerves, and facilitating local or systemic drug action. Conventional liquid nasal dosage forms have not managed to bridge the gaps of precise dosing and targeted central nervous system (CNS) delivery, while more sophisticated formulation approaches are being explored for brain targeting, aiming to enhance bioavailability and therapeutic efficacy.Areas covered: This review focuses on preclinical and clinical evaluation of microemulsions, in-situ gels, nasal powders, and nanocarrier-based formulations. Key pharmacokinetic and pharmacodynamic findings are discussed to evaluate their potential and limitations in improving drug bioavailability and CNS targeting. The existing regulatory framework for approval of products for nose-to-brain drug delivery is also addressed and relative hurdles are discussed.Expert opinion: While nasal drug delivery holds great promise for CNS therapeutics, key challenges remain, including formulation stability, mucosal permeability, patient adherence. Future research should prioritize improving targeting efficiency, overcoming mucociliary clearance, developing user-friendly pharmaceutical products. Personalized medicine and smart delivery systems could further enhance drug targeting and minimize side effects. Continued research and regulatory advancements are essential to fully realize nasal delivery's perspective in CNS therapeutics.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"823-839"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143797455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Closed-loop therapy: recent advancements and potential predictors of glycemic outcomes. 闭环治疗：最近的进展和潜在的预测血糖结局。

Expert opinion on drug delivery Pub Date : 2025-06-01 Epub Date: 2025-04-18 DOI: 10.1080/17425247.2025.2492363

Chloë Royston, Roman Hovorka, Charlotte K Boughton

{"title":"Closed-loop therapy: recent advancements and potential predictors of glycemic outcomes.","authors":"Chloë Royston, Roman Hovorka, Charlotte K Boughton","doi":"10.1080/17425247.2025.2492363","DOIUrl":"10.1080/17425247.2025.2492363","url":null,"abstract":"Introduction: Hybrid closed-loop systems have become the standard of care for managing type 1 diabetes (T1D). Both clinical trials and real-world data have demonstrated that these systems improve glycemic control without increasing the risk of hypoglycemia, while also reducing the overall burden of T1D management. A systematic literature search was conducted using PubMed for studies including individuals with T1D that were published until the end of 2024.Areas covered: In this review, we summarize the safety and efficacy of currently available hybrid closed-loop systems, drawing from key clinical trials and real-world data analyses. We also highlight recent advancements in closed-loop systems, discuss their limitations and barriers to access, and explore future directions for automated insulin delivery. Finally, we explore potential predictors of outcomes for people with T1D to better understand why some individuals respond better to closed-loop systems than others.Expert opinion: Closed-loop systems are advancing rapidly, with a growing focus on enhancing automation through fully closed-loop systems to improve glycemic control and further reduce the burden of management. Identifying the predictors that influence how individuals respond to closed-loop therapy will enable these systems to be optimized. It is crucial to ensure widespread and equitable access to this advanced technology.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"875-892"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7617697/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144055057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current research and future potential of thermogels for sustained drug delivery. 热凝胶用于持续给药的当前研究和未来潜力。

Expert opinion on drug delivery Pub Date : 2025-06-01 Epub Date: 2025-04-16 DOI: 10.1080/17425247.2025.2486350

Pek Yin Michelle Yew, Qianyu Lin, Cally Owh, Pei Lin Chee, Xian Jun Loh

{"title":"Current research and future potential of thermogels for sustained drug delivery.","authors":"Pek Yin Michelle Yew, Qianyu Lin, Cally Owh, Pei Lin Chee, Xian Jun Loh","doi":"10.1080/17425247.2025.2486350","DOIUrl":"10.1080/17425247.2025.2486350","url":null,"abstract":"Introduction: Drug administration is ubiquitous in the healthcare field, and it is crucial to optimize drug delivery methods to improve drug efficacy, reduce systemic toxicity, and enhance patient compliance Thermogels have shown immense potential in drug delivery due to their injectability, biocompatibility, and ability to provide localized and sustained drug release.Area covered: This paper discusses the unique properties of thermogel in relation to drug kinetics and their suitability as a carrier. Different considerations and applications of thermogel drug delivery systems (DDS) were highlighted and their challenges to enter the market discussed. A comprehensive literature search was conducted using major databases such as PubMed, Scopus, and Web of Science. The search employed relevant keywords to identify studies on thermogel DDS. Clinicaltrials.gov was also utilized to determine the current state of clinical studies.Expert opinion: Nonetheless, thermogel holds great promise for the future in DDS with research achieving greater heights in terms of complexity and clinical pursuits. Their flexibility in fabrication and modularity manner makes it a great material to tailor to different drug delivery applications and to be integrated into various biomedical disciplinaries.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"769-786"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143744592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nanovector approach for co-delivery of Alectinib and Hesperidin via inhalational for lung cancer treatment: development, characterization, and preclinical studies. 吸入给药阿勒替尼和橙皮苷用于肺癌治疗的纳米载体方法：发展、表征和临床前研究。

Expert opinion on drug delivery Pub Date : 2025-06-01 Epub Date: 2025-04-08 DOI: 10.1080/17425247.2025.2487585

Saeem Ahmad, Shahnaj Bano, Nasr A Emad, Shadab Alam, Anjali Rathee, Iqra Zai, Jayamanti Pandit, Mohd Aqil, Yasmin Sultana

{"title":"Nanovector approach for co-delivery of Alectinib and Hesperidin via inhalational for lung cancer treatment: development, characterization, and preclinical studies.","authors":"Saeem Ahmad, Shahnaj Bano, Nasr A Emad, Shadab Alam, Anjali Rathee, Iqra Zai, Jayamanti Pandit, Mohd Aqil, Yasmin Sultana","doi":"10.1080/17425247.2025.2487585","DOIUrl":"10.1080/17425247.2025.2487585","url":null,"abstract":"Background: The current study aims to fabricate Nanostructured Lipid Carriers for the co-delivery of Alectinib and Hesperidin (ALB-HSD NLC) for non-small cell lung Cancer (NSCLC) via an inhalational route.Research design and method: The ALB-HSD NLC was fabricated using Melt emulsification followed by the sonication method and optimized using a central composite design. The optimized formulation was evaluated for various in vitro and in vivo studies.Results: The optimized ALB-HSD NLC had satisfactory results for particle size, Zeta Potential, PDI, and entrapment efficiency. The drug release was more than 2.5-fold higher compared to drugs suspension over 72 hr. A549 human lung cell line study shows IC50 for ALB and HSD, were 2.289 µg/mL and 73.52 µg/mL, and the dose-dependent toxicity was 0.0209 μg/mL and 0.5213 μg/mL for ALB-HSD NLC formulation and ALB HSD Suspension, respectively, after 72 hr. The Pharmacokinetic study has demonstrated improved AUC0-t (1.38, 1.57-fold) of ALB and HSD from NLC compared to drug suspension. In vivo studies give significant results on the syngeneic model.Conclusions: The prepared ALB-HSD NLC could be promising drug carriers, and they succeeded in delivering small and efficient doses of ALB and HSD to treat NSCLC.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"893-908"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143775115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction. 修正。

Expert opinion on drug delivery Pub Date : 2025-05-07 DOI: 10.1080/17425247.2025.2501414

引用次数: 0

A look to the future: cyclodextrins and cyclodextrin-based drug delivery to the retina. 展望未来：环糊精和基于环糊精的视网膜药物输送。

Expert opinion on drug delivery Pub Date : 2025-05-01 Epub Date: 2025-03-20 DOI: 10.1080/17425247.2025.2482049

Phatsawee Jansook, Hákon H Sigurdsson, Thorsteinn Loftsson

{"title":"A look to the future: cyclodextrins and cyclodextrin-based drug delivery to the retina.","authors":"Phatsawee Jansook, Hákon H Sigurdsson, Thorsteinn Loftsson","doi":"10.1080/17425247.2025.2482049","DOIUrl":"10.1080/17425247.2025.2482049","url":null,"abstract":"Introduction: Retinal diseases are a leading cause of vision loss, affecting millions of people worldwide. Current treatment options are based on invasive methods such as intravitreal injections. Therefore, there is a need for alternative therapeutic strategies that are both effective and more patient-friendly.Areas covered: Topical drug delivery has gained attention as a preferred noninvasive approach, although it is hindered by several ocular barriers. Cyclodextrin (CD)-based nanoparticles have emerged as a promising strategy to overcome these limitations by enhancing drug permeability in the posterior segment of the eye. This review discusses the potential of CDs as enabling pharmaceutical excipients, their role in improving ocular drug bioavailability, and provides examples of CD-based eye drop formulations currently under development or undergoing clinical trials. Also, the role of CDs as active pharmaceutical agents in ophthalmology is discussed.Expert opinion: CD-based nanoparticle eye drops present a promising solution and have shown clinical success. CDs are approved pharmaceutical excipients for eye drop formulations and can act as active pharmaceutical ingredients for the treatment of inherent retinal diseases. Future innovations in hybrid CD-based delivery systems and integration of novel therapeutic compounds could provide more efficient and targeted treatment options for retinal diseases.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"693-710"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143660062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current insights into drug-coated balloons for peripheral arterial disease. 药物包被球囊治疗外周动脉疾病的最新进展。

Expert opinion on drug delivery Pub Date : 2025-05-01 Epub Date: 2025-03-12 DOI: 10.1080/17425247.2025.2476043

Antonio Micari, Antonino Micari, Vittorio Virga, Francesco Costa, Gianluca Di Bella, Giuseppe Roscitano, Antonio Versace, Giuseppe Vadalà, Giampiero Vizzari

{"title":"Current insights into drug-coated balloons for peripheral arterial disease.","authors":"Antonio Micari, Antonino Micari, Vittorio Virga, Francesco Costa, Gianluca Di Bella, Giuseppe Roscitano, Antonio Versace, Giuseppe Vadalà, Giampiero Vizzari","doi":"10.1080/17425247.2025.2476043","DOIUrl":"10.1080/17425247.2025.2476043","url":null,"abstract":"Introduction: Peripheral artery disease (PAD) is a manifestation of systemic atherosclerosis. It is often associated with coronary and/or cerebral vascular involvement, leading to a higher risk of cardiovascular and cerebrovascular events, among which myocardial infarction, stroke, and death. Cardiovascular prevention has proven effective in reducing the progression of the disease and early diagnosis leads to more rapid initiation of medical therapy. However, revascularization of the diseased segment represents the only solution in the manifest and symptomatic forms of the disease.Areas covered: Surgical treatment has historically represented the first treatment of PAD, which consists in the creation of bypasses excluding the obstructed segment. Nowadays, endovascular treatment represents in many cases the first line of intervention. Drug-coated balloons are a cornerstone solution for the treatment of peripheral lesions and are supported by multiple trials demonstrating their efficacy and safety.Expert opinion: New devices, such as sirolimus-eluting balloons, and also new eluting technologies will further improve the efficacy and the results of peripheral angioplasty. In the next years, we will experience the routinary use of new techniques currently under study. In this review, we will discuss the role of drug-coated balloons in the treatment of PAD.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"629-637"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143574861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The blood-brain barrier as a treatment target for neurodegenerative disorders. 血脑屏障作为神经退行性疾病的治疗靶点。

Expert opinion on drug delivery Pub Date : 2025-05-01 Epub Date: 2025-03-21 DOI: 10.1080/17425247.2025.2480654

Ruslan Rust, Abhay P Sagare, Mingzi Zhang, Berislav V Zlokovic, Kassandra Kisler

{"title":"The blood-brain barrier as a treatment target for neurodegenerative disorders.","authors":"Ruslan Rust, Abhay P Sagare, Mingzi Zhang, Berislav V Zlokovic, Kassandra Kisler","doi":"10.1080/17425247.2025.2480654","DOIUrl":"10.1080/17425247.2025.2480654","url":null,"abstract":"Introduction: The blood-brain barrier (BBB) is a vascular endothelial membrane which restricts entry of toxins, cells, and microorganisms into the brain. At the same time, the BBB supplies the brain with nutrients, key substrates for DNA and RNA synthesis, and regulatory molecules, and removes metabolic waste products from brain to blood. BBB breakdown and/or dysfunction have been shown in neurogenerative disorders including Alzheimer's disease (AD). Current data suggests that these BBB changes may initiate and/or contribute to neuronal, synaptic, and cognitive dysfunction, and possibly other aspects of neurodegenerative processes.Areas covered: We first briefly review recent studies uncovering molecular composition of brain microvasculature and examine the BBB as a possible therapeutic target in neurodegenerative disorders with a focus on AD. Current strategies aimed at protecting and/or restoring altered BBB functions are considered. The relevance of BBB-directed approaches to improve neuronal and synaptic function, and to slow progression of neurodegenerative processes are also discussed. Lastly, we review recent advancements in drug delivery across the BBB.Expert opinion: BBB breakdown and/or dysfunction can significantly affect neuronal and synaptic function and neurodegenerative processes. More attention should focus on therapeutics to preserve or restore BBB functions when considering treatments of neurodegenerative diseases and AD.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"673-692"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143652810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Molecular insights into the antineoplastic potential of apigenin and its derivatives: paving the way for nanotherapeutic innovations. 芹菜素及其衍生物抗肿瘤潜能的分子洞察：为纳米治疗创新铺平道路。

Expert opinion on drug delivery Pub Date : 2025-05-01 Epub Date: 2025-03-17 DOI: 10.1080/17425247.2025.2477664

Debasmita Dutta, Ashique Al Hoque, Brahamacharry Paul, Shahnaz Begum, Uday Aditya Sarkar, Biswajit Mukherjee

{"title":"Molecular insights into the antineoplastic potential of apigenin and its derivatives: paving the way for nanotherapeutic innovations.","authors":"Debasmita Dutta, Ashique Al Hoque, Brahamacharry Paul, Shahnaz Begum, Uday Aditya Sarkar, Biswajit Mukherjee","doi":"10.1080/17425247.2025.2477664","DOIUrl":"10.1080/17425247.2025.2477664","url":null,"abstract":"Introduction: Apigenin, a widely distributed bioactive flavonoid, has recently gained excellent attention among researchers as an effective anticancer drug that can alternate cancer-signaling pathways, induce programmed cell death, and reduce tumor growth in various cancer types. Despite its impressive anti-neoplastic activity, high hydrophobicity, and nonspecific biodistribution make apigenin difficult for pharmaceutical applications.Areas covered: We highlighted the therapeutic potential of apigenin and its derivatives in different cancer types, along with their mechanism of action. Nanoengineered drug delivery systems have remarkable applications in minimizing drug degradation and enhancing the therapeutic efficacy of drugs with sustained release, prolonged blood retention time, and reduced off-target toxicities. This review has evaluated and explored the molecular interactions of this novel flavonoid in various cancer signaling pathways to selectively inhibit neoplastic development in multiple cancer types. To ensure the complete coverage of the explored research area, Google Scholar, PubMed, and Web of Science were used to find not only the most relevant but also connected and similar articles.Expert opinion: A comprehensive overview of apigenin nanotherapy in cancer treatment can establish a platform to overcome its difficulties for pharmaceutical applications and efficient clinical translation from bench to bedside.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"639-658"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143598579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0